This article is for men with metastatic castration-resistant prostate cancer (mCRPC) - prostate cancer that has spread and stopped responding to hormone therapy. If your oncologist ordered a PSMA-PET scan to assess whether you qualify for lutetium Lu-177 vipivotide tetraxetan therapy, this guide explains what your results mean.
To be eligible for Lu-177 PSMA therapy, your scan must show at least one metastatic lesion with PSMA tracer uptake higher than normal liver tissue. Your report's numbers and patterns - including SUV max values, whether uptake is uniform or mixed, and whether any lesions are PSMA-cold - help your nuclear medicine team understand your specific case.
What Is a PSMA-PET Scan?
PSMA stands for prostate-specific membrane antigen. It's a protein on the surface of most prostate cancer cells. More advanced cancer usually expresses more PSMA.
A PSMA-PET scan uses a small radioactive tracer - most often gallium-68 (Ga-68) attached to a PSMA-targeting molecule - that binds to this protein. A PET/CT scanner picks up the signal and shows exactly where your cancer is active. You can read more about how doctors perform the scan in our guide to preparing for your PSMA-PET scan for Lu-177 eligibility.
For Lu-177 therapy to work, your cancer cells must have enough PSMA protein for the treatment molecule to bind to. This is why the scan serves as both a diagnostic tool and an eligibility test.
What Does "PSMA-Avid" Mean?
When a radiologist says a lesion is "PSMA-avid," they mean it is actively taking up the tracer. The cancer cell is expressing PSMA, and the tracer attaches to it. "Avid" simply means the uptake is meaningful - not a faint or background signal.
A lesion that does not take up the tracer is "PSMA-negative" or "PSMA-cold." This matters because Lu-177 uses the same PSMA protein as the scan tracer to target cancer cells. Lu-177 is likely to miss a lesion that is PSMA-cold on your scan.
The Liver as Your Reference Point
Radiologists do not read PSMA uptake alone. They compare each lesion to a reference organ - and the liver is the standard reference point for eligibility decisions.
In the VISION trial - the large clinical study that led to FDA approval of lutetium Lu-177 vipivotide tetraxetan (Pluvicto) - patients were eligible if they had at least one metastatic lesion with tracer uptake visually greater than normal liver tissue. This threshold - a lesion-to-liver ratio greater than 1 - is the most widely used clinical benchmark. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) appropriate use criteria also endorses it as the primary patient selection standard.
In plain terms: if a lesion glows brighter than your liver on the scan, it counts as PSMA-positive for eligibility purposes.
What Is SUV Max, and Does the Number Matter?
SUV max - standardized uptake value maximum - is a number your scanner calculates. It measures how intensely the tracer concentrates in the brightest spot of a lesion. Think of it as a brightness score.
There is no single SUV max number that qualifies or disqualifies all patients. Different eligibility systems use different thresholds:
- The VISION trial used a visual comparison to the liver rather than a fixed SUV max cutoff. A lesion brighter than liver was considered PSMA-positive.
- The TheraP trial, an Australian study that also evaluated Lu-177 PSMA therapy, required an SUV max of at least 20 at one or more sites and at least 10 in measurable soft-tissue lesions, as documented in a published comparison of the two trial eligibility criteria.
- Higher SUV max values generally suggest stronger PSMA expression. Research suggests this may correlate with better response to Lu-177 therapy, though individual outcomes vary.
If your report states "SUV max 22 in the right iliac bone lesion," that would meet most commonly used eligibility thresholds. If it states "SUV max 5," your team would look carefully at whether that lesion still outshines the liver and whether other factors support proceeding.
SNMMI guidance recommends the VISION liver-comparison standard as the primary eligibility tool, since it reflects the criteria used in the largest body of evidence on treatment benefit in mCRPC.
Uptake Patterns: What Your Whole-Body Map Reveals
A PSMA-PET scan shows your whole body, not one lesion. Doctors review the pattern of uptake across all your metastatic sites. Three patterns matter most in eligibility discussions.
Uniform high uptake
All visible lesions - in bone, lymph nodes, and soft tissue - glow strongly above the liver reference. This is the clearest eligibility signal. Lu-177 is likely to reach all active disease sites.
Heterogeneous uptake
Some lesions glow brightly while others are dim or barely visible. Heterogeneous means mixed. When uptake is uneven, your doctor needs to judge whether the low-PSMA lesions are a small fraction of your disease or a significant proportion that Lu-177 is unlikely to treat.
FDG-PSMA mismatch
Some centers perform a combined FDG and PSMA PET scan. FDG is a glucose-based tracer that shows metabolically active cancer. When a lesion glows brightly on FDG but dimly or not at all on PSMA, doctors call this a "mismatch." It suggests that lesion may no longer express PSMA and could be resistant to Lu-177 targeting. Research in a peer-reviewed nuclear medicine journal found that FDG-PSMA mismatch lesions show specific progression patterns during radioligand therapy. Not every center performs combined imaging, but if yours does, this finding carries real clinical weight in the eligibility discussion.
What Happens If Your Uptake Is Low or Borderline?
A borderline scan - where lesions barely exceed liver uptake or where results are mixed across sites - doesn't automatically disqualify you, but it raises important questions. Your nuclear medicine team and oncologist will consider:
- What proportion of your measurable disease is PSMA-positive?
- Are the PSMA-negative sites small or clinically active?
- Has prior treatment affected PSMA expression on your tumor cells?
- Does the overall picture support a reasonable chance of benefit?
Some patients with borderline PSMA expression join clinical trials that explore treatment strategies for lower-uptake disease. Others might benefit more from a different type of treatment. If your doctor said you don't qualify based on a single scan, our article on what a negative or low-uptake PSMA scan means for Lu-177 eligibility in mCRPC covers your next options in more detail.
Does the Number of Lesions Affect Eligibility?
In the VISION trial, patients needed only one PSMA-positive lesion to be eligible. Doctors set no upper limit on the total number of metastases. This differs from some other treatment options that limit therapy to patients with limited, oligometastatic spread.
That said, when a large share of your disease burden is PSMA-cold, the concern is whether the treatment will work. Lu-177 would treat the PSMA-positive sites while PSMA-negative sites could continue to progress. Your treatment team will factor this into the overall recommendation.
Bone Metastases and PSMA Uptake
Many men with mCRPC have metastases primarily or entirely in bone. Bone lesions can absolutely be PSMA-avid - the same liver-uptake comparison applies. Bone-dominant disease was well represented in the VISION trial population. The National Cancer Institute covered the VISION trial results showing benefit in mCRPC patients, which included men with bone metastases. Bone-only disease doesn't automatically mean you're ineligible; it depends on whether those bone lesions are PSMA-avid on your individual scan.
What to Do With Your Scan Results
Your written PSMA-PET report is a starting point - not a final verdict on eligibility. Borderline or heterogeneous uptake requires clinical judgment from someone who regularly reads these scans in the context of radioligand therapy decisions. If your local team is uncertain, or if you want a second reading before committing to travel or a treatment course, have a nuclear medicine physician experienced in Lu-177 eligibility review your DICOM image files - the actual digital scan, not just the written summary.
If you are evaluating treatment in India or internationally and want to know whether your scan shows eligibility before you travel, you can send your scans to the Art of Healing Cancer team for review. Their nuclear medicine team regularly assesses PSMA-PET scans in the context of Lu-177 eligibility.
You can also submit your case via the Lutetium Therapy eligibility review form. If your scan doesn't clearly show Lu-177 eligibility, the review can also suggest alternative options worth discussing with your oncologist.
For more on what a specialist review involves, see our article on getting a second opinion on Lu-177 PSMA eligibility and how expert reviews work.
When to Talk to Your Doctor
Raise these topics with your oncologist or nuclear medicine physician:
- Your PSMA-PET report includes terms you don't fully understand or findings that seem contradictory
- You were told you don't qualify, but the decision was based on a borderline or low-uptake result
- Your scan showed FDG-PSMA mismatch and you want to understand what that means for next steps
- Your PSA is rising but your PSMA scan is negative or shows only faint uptake
- You are planning to travel abroad for Lu-177 therapy and need to confirm your current eligibility
This article provides general information, not medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Does a single PSMA-avid lesion qualify me for Lu-177 therapy?
It may. The VISION trial required only one PSMA-positive lesion - defined as uptake greater than normal liver on a Ga-68 PSMA-PET scan - to meet eligibility. You do not need all your lesions to be positive. However, having many PSMA-negative sites alongside the positive one is factored into the overall clinical judgment by your treatment team.
What does it mean if my SUV max is low - say, below 10?
A low SUV max does not automatically mean you are ineligible, but it does mean your team will look more carefully at your scan. If the lesion still registers above liver uptake, it may still count as PSMA-positive under the VISION standard, which is the most widely used eligibility benchmark. If SUV max is below 10 across all sites, some trial protocols would consider that borderline or low-PSMA disease, and a detailed clinical review is warranted before any decision is made.
My report says heterogeneous PSMA uptake. Does that mean I do not qualify?
Not necessarily. Heterogeneous means different lesions show different amounts of uptake. Your eligibility depends on whether enough of your disease is PSMA-positive for treatment to have a meaningful chance of reaching it. This is a clinical judgment call that requires review by a specialist in radioligand therapy - not a simple read of the written report. A second opinion from a nuclear medicine physician experienced in Lu-177 eligibility is often worthwhile in this situation.
What is an FDG-PSMA mismatch and does it rule out Lu-177?
An FDG-PSMA mismatch happens when a lesion lights up on an FDG glucose tracer scan but not on the PSMA scan. It suggests that specific lesion may not express PSMA and could be resistant to Lu-177 targeting. If only a small number of lesions show this pattern, it may not rule out treatment. But if a large share of your visible disease shows mismatch, your team will weigh whether Lu-177 is likely to benefit you meaningfully. Not all centers perform combined FDG/PSMA imaging.
Can I get my scan re-read if I was told I do not qualify?
Yes. PSMA-PET scan interpretation involves judgment, particularly for borderline or heterogeneous cases. A second opinion from a center specializing in PSMA imaging and radioligand therapy eligibility is reasonable and sometimes leads to a different conclusion. When seeking a second reading, bring your original DICOM image files - the digital scan data - not just the written report. The written report alone does not give the reviewing physician enough to make a definitive assessment.
How long is a PSMA-PET scan valid for eligibility purposes?
There is no universal expiry period, but most treatment centers want to see a scan performed within roughly three to six months before starting therapy. Your disease can change over time, including PSMA expression levels, so a scan done more than six months ago may need to be repeated to confirm current eligibility before Lu-177 cycles begin. Your treatment team will advise based on how your disease has been behaving.
